从不吸烟肺腺癌患者一线EGFR-TKI治疗无进展生存的遗传修饰因子
该研究在128例接受一线EGFR-TKI治疗的不吸烟女性肺腺癌患者中开展全基因组关联分析,识别与无进展生存(PFS)相关的遗传变异,并在198例随访队列和153例独立队列中验证。发现4q12区域单核苷酸多态性(SNPs)与PFS在全基因组水平显著相关(P < 10^-8),估计风险比大于4,且与EGFR及邻近基因neuromedin-U表达相关。
要点
- 4q12区域SNPs与一线EGFR-TKI治疗的不吸烟女性肺腺癌患者PFS显著相关。
- 该关联在随访队列和独立非小细胞肺癌队列中均得到重复验证。
- 这些SNPs与EGFR及neuromedin-U表达相关,可能作为预后生物标志物。
核心结论
- 4q12区域遗传变异值得进一步研究,以评估其作为接受TKI治疗患者PFS药物基因组预测因子的潜力,并理解其影响PFS的生物学机制。
研究设计与样本
- 全基因组关联研究纳入128例接受一线EGFR-TKI治疗的不吸烟女性肺腺癌患者,显著SNPs在198例随访队列和153例独立队列中验证。
主要发现
- 4q12区域SNPs与PFS在全基因组水平显著相关(P < 10^-8),估计风险比大于4。
- 该关联在较大相似队列和独立非小细胞肺癌队列中重复验证。
- 这些SNPs与EGFR表达及邻近基因neuromedin-U表达相关。
- 这些SNPs与EGFR突变状态或Bcl2-interacting mediator of cell death基因多态性无关。
临床怎么用
- 4q12区域SNPs可能作为接受一线EGFR-TKI治疗肺腺癌患者的预后生物标志物,但需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Patients with non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR) are relatively sensitive to EGFR-tyrosine kinase inhibitor (TKI) treatment and have longer progression-free survival (PFS) when treated with EGFR-TKI compared with platinum-based chemotherapy. However, many patients with advanced NSCLC who have mutated EGFR do not respond to first-line EGFR-TKI treatment and still have shorter PFS. OBJECTIVES: The aim of this study was to identify genetic variants associated with PFS among patients with lung adenocarcinoma who were treated with first-line EGFR-TKIs. METHODS: A genome-wide association study on PFS was performed in never-smoking women diagnosed with lung adenocarcinoma and who were treated with first-line EGFR-TKIs (n = 128). Significant single-nucleotide polymorphisms (SNPs) were selected for follow-up association analysis (n = 198) and for replication assay in another independent cohort (n = 153). MEASUREMENTS AND MAIN RESULTS: We identified SNPs at 4q12 associated with PFS at genome-wide significance (P < 10-8) and with an estimated hazard ratio of more than 4. This association was also replicated in a larger but similar cohort and in an independent NSCLC cohort. Follow-up functional analyses showed that these SNPs were associated with the expression of EGFR, which encodes the TKI target, and with a nearby gene neuromedin-U, which encodes a G protein-coupled receptor ligand known to be involved in the progression of NSCLC. Considering these as possible prognostic biomarkers for the treatment of patients with late-stage lung cancer, we found that these SNPs were not associated with EGFR mutation status or with polymorphism of the Bcl2-interacting mediator of cell death gene. CONCLUSIONS: Genetic variants in 4q12 merit further investigation to assess their potential as pharmacogenomic predictors for and to understand the biology underlying its influence on PFS in patients treated with TKI therapy.
引用
- Chang IS, Jiang SS, Yang JC, et al. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. Am J Respir Crit Care Med. 2017. PMID: 27669169. doi:10.1164/rccm.201602-0300OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。